• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Nivolumab combination therapies improved overall survival in patients with advanced esophageal squamous cell carcinoma

byJamie ParkandSze Wah Samuel Chan
February 9, 2022
in Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone.

2. Common treatment-related adverse events in the nivolumab combination groups were nausea, decreased appetite and stomatitis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Esophageal cancer is known as the 6th leading cause of cancer-related deaths worldwide. There is scarce knowledge on the treatment for patients who are refractory or intolerant to the standard therapies (fluoropyrimidine plus platinum-based chemotherapy). Nivolumab is a PD-1 inhibitor that is currently approved for use for a variety of cancers such as advanced squamous and non-squamous non-small-cell lung cancer, melanoma, and Hodgkin’s lymphoma. Previously, combination therapy of nivolumab and ipilimumab has led to longer overall survival compared to chemotherapy or nivolumab monotherapy in several solid tumours. Therefore, this study aimed to explore the safety and efficacy of nivolumab in combination with chemotherapy or ipilimumab in patients with advanced esophageal squamous cell carcinoma. Both nivolumab plus chemotherapy and nivolumab plus ipilimumab significantly prolonged overall survival compared to chemotherapy alone in the overall population. Both combination treatments also significantly improved the overall survival in patients with tumour-cell PD-L1 expression of 1 % or greater.  Nausea, decreased appetite and stomatitis were common treatment-related adverse events that were reported in the nivolumab combination groups. Out of the 3 treatment groups, the incidence of grade 3 or 4 treatment-related adverse events was the highest in the nivolumab plus chemotherapy group. The main limitation of the analyses included not comparing the efficacy between the two combination therapy groups. Overall, this study demonstrated that nivolumab plus chemotherapy or ipilimumab could be a potential treatment for advanced esophageal squamous cell carcinoma. However, further investigation is required to examine the difference in efficacy between different combination treatments with nivolumab.

Click to read the study in The New England Journal of Medicine

Relevant Reading: Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

Active Surveillance vs Standard Surgery Post-Neoadjuvant Chemoradiotherapy for Esophageal Cancer

In-Depth [randomized controlled trial]: This was an open-label, global, phase III study. Patients were enrolled if they had unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma. A total of 970 patients were randomized to receive nivolumab plus chemotherapy, nivolumab plus ipilimumab or chemotherapy alone. The patient demographics and clinical characteristics were well-balanced in all three treatment groups. The minimum follow-up period was 13 months. The overall survival was significantly improved in both combination therapy groups compared to chemotherapy alone in the overall population (nivolumab plus chemotherapy: hazard ratio [HR]: 0.74, 99.1%, confidence interval [CI]: 0.58-0.96; nivolumab plus ipilimumab: HR: 0.78, 98.2% CI: 0.62-0.98). Both combination treatments also significantly improved the overall survival in patients with tumour-cell PD-L1 expression of 1% or greater (nivolumab plus chemotherapy: HR: 0.54, 99.5% CI: 0.37-0.80; nivolumab plus ipilimumab: HR: 0.64, 98.6% CI: 0.46-0.90). Common treatment-related adverse events of any grade in the nivolumab combination groups were nausea (nivolumab + chemotherapy: 59%, nivolumab + ipilimumab: 8%), decreased appetite (nivolumab + chemotherapy: 43%, nivolumab + ipilimumab: 6%) and stomatitis (nivolumab + chemotherapy: 32%, nivolumab + ipilimumab: 4%). The incidence of grade 3 or 4 treatment-related adverse events in the nivolumab plus chemotherapy group (47%) was higher compared to the other groups (nivolumab + ipilimumab: 32%, chemotherapy alone: 36%). Immune-related adverse events included rash, pruritis and hypothyroidism occurring most frequently in the dual immunotherapy group. Grade 3-4 immune events mostly occurred in the dual immunotherapy group and included hepatic, dermatological and endocrine dysfunction.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: esophageal canceripilimumabNivolumab
Previous Post

Systematic review of Kawasaki disease shows excellent long-term survival

Next Post

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Incidence of esophageal cancer subtypes vary drastically globally and by gender
Chronic Disease

Active Surveillance vs Standard Surgery Post-Neoadjuvant Chemoradiotherapy for Esophageal Cancer

March 24, 2025
Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy
Gastroenterology

Perioperative chemotherapy improves survival in esophageal cancer

March 6, 2025
Next Post
Insulin costs rose exponentially, regardless of formulation or patent

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

Children born late preterm birth at higher odds to fail standardized tests

Neonatal deaths in premature infants correlate with gestational age at birth

Increased risk of stillbirth recurrence after a previous stillbirth

Wellness Check: Spirituality

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.